ECI 830
Alternative Names: ECI-830Latest Information Update: 31 Jan 2025
Price :
$50 *
At a glance
- Originator Novartis Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; HER2 negative breast cancer; Solid tumours
Most Recent Events
- 10 Dec 2024 Preclinical trials in Breast cancer in USA (unspecified route) before December 2024 (NCT06726148)
- 10 Dec 2024 Preclinical trials in HER2-negative-breast-cancer in USA (unspecified route) (before December 2024 (NCT06726148)
- 10 Dec 2024 Preclinical trials in Solid tumours in USA (unspecified route) before December 2024 (NCT06726148)